Treatment of MEN2A in a Child with ATA Moderate-Risk Category and RET Germline Mutation

This protocol addresses the management of Multiple endocrine neoplasia type 2A (MEN2A) in a pediatric patient classified in the ATA moderate-risk (ATA-MOD) category, carrying a RET germline mutation other than M918T, C634, or A883F. The specific mutation type and patient age together define the risk tier and drive clinical decision-making.

Clinical Scenario

Children in the ATA-MOD category should have a physical examination, ultrasound of the neck, and measurement of serum calcitonin (Ctn) levels beginning around 5 years of age. Ongoing surveillance informs the timing of any intervention.

Approach (partial overview)

Surgical intervention is part of the management strategy for this risk category, with the timing of the procedure driven by serum calcitonin surveillance rather than a fixed age alone. The full protocol specifies the conditions and sequence that guide this decision.

Complete regimen details, including precise timing criteria and procedural scope, are available in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1089/thy.2014.0335

Children in the ATA-MOD category should have a physical examination, US of the neck, and measurement of serum Ctn levels beginning around 5 years of age.

The timing of thyroidectomy should be based on the detection of an elevated serum Ctn level; however, 6-month or annual evaluations may extend to several years or decades.

Children in the ATA-MOD category should have a thyroidectomy in childhood or young adulthood, the timing depending primarily on serum Ctn levels.

View source ↗